Originally published here.
In this special edition of the Biotech Pulse podcast, we feature a live panel discussion hosted in partnership with the University of Cambridge Judge Business School and Forbion, a leading life sciences venture capital firm. The event, titled "Smart Capital, Leveraged Science: How VCs Unlock Biotech Potential", brings together prominent voices from across the biotech investment landscape to explore how venture capital can catalyze transformative science and drive scalable innovation in healthcare. Forbion’s strategic approach to company building, long-term relationships, and operational support serves as a central theme throughout the discussion.
The panel includes Sander Slootweg, Managing Partner at Forbion; Nektarios (Aris) Oraiopoulos, PhD, Professor of Operations & Technology Management at Cambridge Judge Business School; Mihriban Tuna, PhD, CEO of Immutrin; and Carmine Circelli, PhD, Director of Direct Investments (Life Sciences) at the British Business Bank. Together, they explore how rigorous due diligence, the evolution of syndication models, and cross-functional collaboration between investors and entrepreneurs shape the future of biotech.
With case studies, real-world fundraising perspectives, and in-depth commentary on European ecosystem dynamics, this episode offers a timely and insightful conversation for biotech founders, investors, and policy stakeholders interested in how smart capital unlocks lasting scientific and commercial impact.
About The Biotech Pulse - a Forbion podcast
Forbion is a leading life sciences venture capital firm founded in the Netherlands, helping companies bridge research and development through our team's expertise in drug development and company building. For over 15 years, we have invested in over 100 companies backing exciting therapies that we believe have the potential to impact the future of medicine. The Biotech Pulse is a forum where we speak about all things biotech with diverse stakeholders in the life sciences industry.
